Please type a plus sign (+) inside this box →

PTO/SB/08A (10-96 Approved for use through 10/31/99. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Page	erwork Reduction Act of	1995, no persons	are required to respond to a collection of information un	niess it contains a valid OMB control number			
Substitute for form 1449A/PTO				Complete if Known			
* * * * * * * * * * * * * * * * * * *	STA	TEME	TION DISCLOSURE NT BY APPLICANT ny sheets as necessary)	Application Number	09/709,045		
			•	Filing Date	November 10, 2000		
				First Named Inventor	M. Rigdon Lentz		
				Group Art Unit	1647		
				Examiner Name	Lorraine Spector		
Sheet	1	of	2	Attorney Docket Number	LEN 102		

				U.S. PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	US Patent Docur	nent Na	ame of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
			Code ² known)				
		5,359,037	Wallach		10-25-1994		
		6,232,446	Wallach		05-15-2001		
	•	6,982,089	Tobinick		01-03-2006		
		7,236,776	Hauptman	n	07-03-2007		
		<u> </u>					

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹				Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
		Office.3	Office. ³ Number ⁴]			
		JP	6 296860 (Abstract)		Asahi Medical Co. Ltd.	10-25-1994		
		PCT	WO 97/014964		Heinrich, et al.	04-24-1997		
		-						

Examiner's	Date Considered	
Signature		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Sheet

Please type a plus sign (+) inside this box → +

of

PTO/SB/08A (16) 9(
Approved for use through 10/31/99. OMB 0651-0	03
Patent and Trademark Office: U.S. DEPARTMENT OF COMMER	₹CF

LEN 102

		. Otolitona introduction and of the fact that the contract of the contract of	
e Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information ur	tiess it contains a valid OMB control number		
Substitute for form 1449A/PTO	Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	09/709,045	
(use as many sheets as necessary)			
	Filing Date	November 10, 2000	
	First Named Inventor	M. Rigdon Lentz	
	Group Art Unit	1647	
	Examiner Name	Lorraine Spector	

Attorney Docket Number

Ē	T-14 1441-1441-1441-1441-1441-1441-1441-	OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Initiats* No.1 item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T²
		SUZUKI, "A prospect of anti-cytokine therapy,", Igaku no Ayumi, Japan, Ishiyaku Publishers, Inc., 167(5):432-435 (1993).	
		OLSSON, "Isolation and characterization of a tumor necrosis factor binding protein from urine", <i>Eur. J. Haematol.</i> , 42(3):270-275 (1989).	
		PEETRE, "A tumor necrosis factor binding protein is present in human biological fluids", <i>Eur. J. Haematol.</i> , 41(3):414-419 (1988).	

		·	
WANTED TO THE TOTAL THE TOTAL TO THE TOTAL TOTAL TO THE T			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CMW/

Examiner's	(Charle M. Mandered)	Date Considered	11/08/2011	
Signature	/Cherie Ivi. vvoodward/	i .	11/00/2011	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.